The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 first-in-human study of interferon beta (IFNβ) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non–small-cell lung cancer (NSCLC).
 
Andreas Nicholas Saltos
Honoraria - MJH Life Sciences (I)
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Lilly; Zymeworks
Research Funding - AstraZeneca (Inst); BioAtla (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Genmab (Inst); Lilly (Inst); Memgen (Inst); Mersana (Inst); Novartis (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Prime Oncology
 
Christy Arrowood
No Relationships to Disclose
 
Georgia Beasley
Honoraria - National Comprehensive Cancer Network
Consulting or Advisory Role - Cardinal Health; Regeneron
Research Funding - Checkmate Pharmaceuticals (Inst); Delcath Systems (Inst); Istari Oncology (Inst); Oncosec (Inst); Replimune (Inst)
 
James Ronald
No Relationships to Disclose
 
Ghassan El-Haddad
Stock and Other Ownership Interests - Johnson & Johnson
Consulting or Advisory Role - Bayer; Boston Scientific; Canon Medical System; NorthStar Medical Radioisotopes; Novartis; TERUMO
 
Luiziane Guerra-Guevara
No Relationships to Disclose
 
Uzma Khan
No Relationships to Disclose
 
Steven Wolf
No Relationships to Disclose
 
Lin Gu
No Relationships to Disclose
 
Xiaofei F. Wang
No Relationships to Disclose
 
Dana Foresman
No Relationships to Disclose
 
Xiaoqing Yu
No Relationships to Disclose
 
Mark J. Cantwell
Employment - Memgen
Leadership - Memgen
Stock and Other Ownership Interests - Memgen
Patents, Royalties, Other Intellectual Property - Multiple patents related to oncolytic virus technology
 
Scott Joseph Antonia
Consulting or Advisory Role - Achilles Therapeutics; Amgen; Bristol-Myers Squibb; Celsius Therapeutics; EMD Serono; G1 Therapeutics; GlaxoSmithKline; Glympse Bio; Memgen; Merck; RAPT Therapeutics; Samyang; Tarus Therapeutics; Venn Therapeutics
Patents, Royalties, Other Intellectual Property - Oncolytic Virus
Travel, Accommodations, Expenses - Achilles Therapeutics; Amgen; Celsius Therapeutics; RAPT Therapeutics
 
Amer A Beg
Stock and Other Ownership Interests - Alaunos Therapeutics; Cellectar
Consulting or Advisory Role - Memgen
Research Funding - Bristol-Myers Squibb/Medarex; Memgen
Patents, Royalties, Other Intellectual Property - Gene signature for the prediction of NF-kappaB activity Patent number: 9115388; IMMUNE CHECKPOINT INHIBITOR AND HDAC INHIBITOR COMBINATION THERAPY STRATEGY; ONCOLYTIC VIRUS OR ANTIGEN PRESENTING CELL MEDIATED CANCER THERAPY USING TYPE I INTERFERON AND CD40-LIGAND (Pending patent)
 
Neal E. Ready
Consulting or Advisory Role - Abbvie; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Celgene; G1 Therapeutics; Jazz Pharmaceuticals; Merck; Merck Serono; Novartis; Pfizer; Regeneron; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Jazz Pharmaceuticals
Research Funding - Bristol-Myers Squibb; Memgen (Inst); Merck